83 related articles for article (PubMed ID: 516362)
1. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
3. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
Sallan SE; Cronin C; Zelen M; Zinberg NE
N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
5. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
Colls BM; Ferry DG; Gray AJ; Harvey VJ; McQueen EG
N Z Med J; 1980 Jun; 91(662):449-51. PubMed ID: 6250106
[TBL] [Abstract][Full Text] [Related]
6. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
Sallan SE; Zinberg NE; Frei E
N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
9. Delta-9-tetrahydrocannabinol as an antiemetic.
Anderson PO; McGuire GG
Am J Hosp Pharm; 1981 May; 38(5):639-46. PubMed ID: 6269423
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
[TBL] [Abstract][Full Text] [Related]
11. [Polychemotherapy of lymphomas. Results of a selection of 32 cases diagnosed in stage III and stage IV and not previously treated].
Neretto G; Giovanelli E; Agricola R; Furno F
Minerva Med; 1978 Oct; 69(49):3367-71. PubMed ID: 724146
[No Abstract] [Full Text] [Related]
12. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
13. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.
Cunningham J; Mauch P; Rosenthal DS; Canellos GP
Cancer Treat Rep; 1982 Apr; 66(4):1015-22. PubMed ID: 7074629
[TBL] [Abstract][Full Text] [Related]
14. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.
Steele N; Gralla RJ; Braun DW; Young CW
Cancer Treat Rep; 1980; 64(2-3):219-24. PubMed ID: 6250699
[TBL] [Abstract][Full Text] [Related]
15. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study.
Hamers J
Biomedicine; 1978 Nov; 29(7):242-4. PubMed ID: 371690
[TBL] [Abstract][Full Text] [Related]
17. Delta-9-tetrahydrocannabinol (THC) as an antiemetic.
Kluin-Nelemans JC; Meuwissen OJ; Nelemans FA; Maes RA
N Engl J Med; 1980 Jun; 302(24):1364-5. PubMed ID: 6246424
[No Abstract] [Full Text] [Related]
18. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
19. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
[TBL] [Abstract][Full Text] [Related]
20. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]